O
CPRX

OrbiMed’s Catalyst Pharmaceutical CPRX Stock Holding History

OrbiMed’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-416,900
Closed -$9.05M – 114
2025
Q2 		$9.05M Buy
+416,900
New +$9.84M 0.23% 62
2018
Q4 		– Sell
-1,102,000
Closed -$4.17M – 135
2018
Q3 		$4.17M Buy
+1,102,000
New +$3.45M 0.05% 131
2014
Q3 		– Sell
-1,895,000
Closed -$4.79M – 135
2014
Q2 		$4.79M Hold
1,895,000
– – 0.06% 111
2014
Q1 		$4.28M Hold
1,895,000
– – 0.05% 121
2013
Q4 		$3.69M Hold
1,895,000
– – 0.05% 103
2013
Q3 		$5.78M Buy
+1,895,000
New +$3.19M 0.1% 97

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

OrbiMed's CPRX Position: Q3 2025 in Review

OrbiMed sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 416,900 shares — an estimated $9.05M sold.

OrbiMed first reported a position in CPRX in Q3 2013 and held it in 6 quarters. The position peaked at $9.05M in Q2 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • OrbiMed reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • OrbiMed sold 416,900 Catalyst Pharmaceutical shares in Q3 2025, an estimated $9.05M.
  • OrbiMed first reported a position in Catalyst Pharmaceutical in Q3 2013 and held it in 6 quarters.
  • OrbiMed's Catalyst Pharmaceutical position peaked at $9.05M in Q2 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.